Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

This collaboration follows positive results from MetaVia's 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both ...

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the ...

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without type 2 diabetes, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction ...

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...